![]() |
|
|
Vol. 280, Issue 3, 1383-1391, 1997
Neuronal Excitability Section, Epilepsy Research Branch, National
Institute of Neurological Disorders and Stroke, National Institutes of
Health, Bethesda, Maryland
Felbamate and meprobamate are structurally related propanediol
dicarbamates that possess distinct pharmacological profiles. Felbamate
is a minimally sedative, broad-spectrum anticonvulsant, whereas
meprobamate is a strong sedative-anxiolytic agent. Previously, we
reported that felbamate potentiates
-aminobutyric acidA
(GABAA) receptor Cl
currents and inhibits
N-methyl-D-aspartate (NMDA) receptor currents. Here we
further characterized the interaction of the two dicarbamates with
GABAA receptors to determine the basis for their
pharmacological differences. In whole-cell voltage-clamp recordings
from cultured rat hippocampal neurons, meprobamate enhanced GABA-evoked
responses in a concentration-dependent manner and, at high
concentrations (>1 mM), exhibited a separate channel-blocking effect
that limited the magnitude of GABAA receptor potentiation.
At equivalent concentrations, meprobamate produced substantially
greater potentiation than did felbamate. Furthermore, meprobamate (but
not felbamate), in the absence of GABA, directly activated
Cl
currents that could be attenuated by the
GABAA receptor antagonists bicuculline and picrotoxin. The
mean deactivation time constant of whole-cell currents evoked by 10 mM
meprobamate (110 ms) or 1 and 3 µM GABA (180 ms) were faster than the
deactivation time constant of 10 mM meprobamate (490 ms) or 3 mM
felbamate (470 ms) in the presence of GABA. Meprobamate and felbamate
prolonged the mean burst duration of GABA-activated unitary currents in excised outside-out membrane patches. In addition, at high
(supratherapeutic) concentrations, meprobamate blocked NMDA-activated
currents. We conclude that felbamate and meprobamate have
barbiturate-like modulatory actions on GABAA receptors, but
meprobamate has greater activity and, unlike felbamate, is able to
directly activate the receptor.
This article has been cited by other articles:
![]() |
L. A. Gonzalez, M. B. Gatch, C. M. Taylor, C. L. Bell-Horner, M. J. Forster, and G. H. Dillon Carisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo Studies J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 827 - 837. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Remy and H. Beck Molecular and cellular mechanisms of pharmacoresistance in epilepsy Brain, January 1, 2006; 129(1): 18 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Kuo, B.-J. Lin, H.-R. Chang, and C.-P. Hsieh Use-Dependent Inhibition of the N-Methyl-D-aspartate Currents by Felbamate: a Gating Modifier with Selective Binding to the Desensitized Channels Mol. Pharmacol., February 1, 2004; 65(2): 370 - 380. [Abstract] [Full Text] [PDF] |
||||